CVN424 150 mg for parkinson disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 14 Aug 2024: Trial registered, NCT06553027
  2. 20 Sep 2024: Trial started, NCT06553027

The trials

NCT06006247: Early Parkinson's Disease Monotherapy With CVN424

State
Completed
Phase
Phase 2
People
64 taking part
Started
11 Sep 2023
Primary completion
30 Jan 2025
Arms
CVN424 150 mg
Results
Posted on the registry
  1. 23 Aug 2023: Trial registered
  2. 11 Sep 2023: Trial started
  3. 13 Feb 2025: Trial completed
  4. 23 Mar 2026: Trial results posted

NCT06553027: To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications

State
Under way
Phase
Phase 3
People
330 planned
Started
20 Sep 2024
Primary completion
Aug 2026
Arms
CVN424 150 mg
Results
None posted
  1. 14 Aug 2024: Trial registered
  2. 20 Sep 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.